{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:38:00Z","timestamp":1794026280064,"version":"4.8.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.xcrm.2025.102446","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T06:48:18Z","timestamp":1762584498000},"page":"102446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells"],"prefix":"10.1016","volume":"6","author":[{"given":"Ravindra","family":"Gujar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Bahador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Algazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Court","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lev","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102446_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102446_bib2","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3389\/fimmu.2019.01654","article-title":"Cytotoxic chemotherapy as an immune stimulus: A molecular perspective on turning up the immunological heat on cancer","volume":"10","author":"Opzoomer","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102446_bib3","article-title":"Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2025.102446_bib4","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102446_bib5","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102446_bib6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study","volume":"41","author":"Harrington","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102446_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11060-017-2668-5","article-title":"Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy","volume":"136","author":"Lin","year":"2018","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.xcrm.2025.102446_bib8","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.canlet.2018.01.050","article-title":"Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy","volume":"419","author":"Wu","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2025.102446_bib9","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1158\/1538-7445.AM2023-6390","article-title":"Abstract 6390: N17350 is an emerging therapeutic modality that selectively kills cancer cells and stimulates anti-tumor immunity","volume":"83","author":"Gujar","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102446_bib10","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1538-7445.AM2024-5895","article-title":"Abstract 5895: N17350 kills cancer cells, spares immune cells, and regresses CDX tumors from chemotherapy naive and experienced patients","volume":"84","author":"Cui","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102446_bib11","series-title":"Regular and Young Investigator Award Abstracts","first-page":"A1498","article-title":"1344 N17350 combines selective cancer killing with adaptive immune activation to eradicate tumors","author":"Cui","year":"2023"},{"key":"10.1016\/j.xcrm.2025.102446_bib12","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41416-020-0763-4","article-title":"Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases","volume":"122","author":"Masoodi","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102446_bib13","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.cell.2021.04.016","article-title":"Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis","volume":"184","author":"Cui","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102446_bib14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2025.102446_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061641","article-title":"Fluoropyrimidine Modulation of the Anti-Tumor Immune Response-Prospects for Improved Colorectal Cancer Treatment","volume":"12","author":"Gmeiner","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2025.102446_bib16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2025.102446_bib17","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2025.102446_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","article-title":"Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery","volume":"5","author":"Mosely","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102446_bib19","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s42003-024-06930-y","article-title":"HMGB2-induced calreticulin translocation required for immunogenic cell death and ferroptosis of cancer cells are controlled by the nuclear exporter XPO1","volume":"7","author":"Fan","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xcrm.2025.102446_bib20","article-title":"Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102446_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/978-1-4939-8885-3_21","article-title":"Gold standard assessment of immunogenic cell death in oncological mouse models","volume":"1884","author":"Humeau","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2025.102446_bib22","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.955691","article-title":"Consensus guidelines for the detection of immunogenic cell death","volume":"3","author":"Kepp","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2025.102446_bib23","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1002\/cam4.5784","article-title":"Characterization of immune cell populations in syngeneic murine tumor models","volume":"12","author":"Snipstad","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.xcrm.2025.102446_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13058-024-01844-3","article-title":"Evaluating the immunologically \u201ccold\u201d tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models","volume":"26","author":"Lu","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102446_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102446_bib26","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102446_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41420-025-02435-7","article-title":"ABCB1 confers resistance to carboplatin by accumulating stem-like cells in the G2\/M phase of the cell cycle in p53null ovarian cancer","volume":"11","author":"Lee","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.xcrm.2025.102446_bib28","article-title":"Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue","volume":"12","author":"Loria","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2025.102446_bib29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102446_bib30","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/s41467-023-37580-z","article-title":"A neutrophil mimicking metal-porphyrin-based nanodevice loaded with porcine pancreatic elastase for cancer therapy","volume":"14","author":"Cui","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102446_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.149902","article-title":"An elastase nanocomplex with metal cofactors for enhancement of target protein cleavage activity and synergistic antitumor effect","volume":"485","author":"Zhu","year":"2024","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.xcrm.2025.102446_bib32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.bbagrm.2015.09.008","article-title":"Histone H1 alterations in cancer","volume":"1859","author":"Scaffidi","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.xcrm.2025.102446_bib33","article-title":"Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma","volume":"9","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102446_bib34","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2025.102446_bib35","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/bloodadvances.2020001797","article-title":"Lingering effects of chemotherapy on mature T cells impair proliferation","volume":"4","author":"Das","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2025.102446_bib36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1440-1827.2011.02755.x","article-title":"Histone H1 expression in human prostate cancer tissues and cell lines","volume":"62","author":"Sato","year":"2012","journal-title":"Pathol. Int."},{"key":"10.1016\/j.xcrm.2025.102446_bib37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(03)00719-0","article-title":"Involvement of histone H1.2 in apoptosis induced by DNA double-strand breaks","volume":"114","author":"Konishi","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102446_bib38","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/nsb1203-983","article-title":"Histone H1.2 as a trigger for apoptosis","volume":"10","author":"Yan","year":"2003","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.xcrm.2025.102446_bib39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41467-017-00338-5","article-title":"Linker histone H1 prevents R-loop accumulation and genome instability in heterochromatin","volume":"8","author":"Bayona-Feliu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102446_bib40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrm.2017.94","article-title":"Emerging roles of linker histones in regulating chromatin structure and function","volume":"19","author":"Fyodorov","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2025.102446_bib41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-020-3017-y","article-title":"Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture","volume":"589","author":"Yusufova","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102446_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001806","article-title":"KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma","volume":"8","author":"Ferrucci","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102446_bib43","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1182\/blood.V84.7.2221.2221","article-title":"Lymphocyte depletion during treatment with intensive chemotherapy for cancer","volume":"84","author":"Mackall","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102446_bib44","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102446_bib45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102446_bib46","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1158\/1538-7445.AM2024-6578","article-title":"Abstract 6578: N17465, a systemically deliverable elastase, attenuates tumorigenesis and stimulates anti-tumor immunity","volume":"84","author":"Gujar","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102446_bib47","series-title":"Regular and Young Investigator Award Abstracts","first-page":"A1456","article-title":"1297 NEU-002 leverages a cancer specific innate immune pathway to induce immunogenic cell death and stimulate anti-tumor immunity","author":"Gujar","year":"2024"},{"key":"10.1016\/j.xcrm.2025.102446_bib48","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.cmet.2014.08.010","article-title":"Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages","volume":"20","author":"Kratz","year":"2014","journal-title":"Cell Metab."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T20:45:23Z","timestamp":1766177123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125005191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2666379125005191"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102446","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102446"}}